Oncology

Risks of genitourinary and gastrointestinal toxicity were reduced significantly, but longer follow-up is necessary to examine potential future issues.

A panel of experts discuss the state of biosimilars today and the importance of standardizing knowledge of the field.

Rates of hospitalizations and mortality from COVID-19 were more than 4 times lower in 2022 compared to 2021, as the virus become less severe with new mutations, a recent study found.

Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.

The results of a study showed that the median progression-free survival was shorter for patients with advanced breast cancer who use proton pump inhibitors with palbociclib.

The updated version of the Oncology Care Model (OCM) incentivizes value-based care over volume, but some wonder if it is enough.

Co-developers Incyte and Syndax will submit a biologics license application to the FDA at the end of 2023 based on the results of a phase 2 trial among adult and pediatric patients with chronic graft-versus-host disease.

Treatment providers have been forced to adapt and make potentially life-altering decisions for patients due to persistent chemotherapy drug shortages, all while solutions from the FDA and drug manufacturers remain scant.

Data suggest the therapy can induce prolonged clinical benefit, even after treatment discontinuation.

Building on promising prior research, ERβ was found to prevent aggressive forms of breast cancer from metastasizing.

Previous research has determined the role of dysregulation in the evolution of cancers but lacked investigation of the ability of these mutations to predict different forms and aggressiveness of cancer.

Amivantamab-vmjw in combination with chemotherapy could assist patients diagnosed with non–small cell lung cancer when chemotherapy alone did not show benefit.

There are currently no effective treatments for CIPN prevention.

Quitting treatment may significantly improve severe hypertension in patients with hepatocellular carcinoma.

These data support a paradigm shift in the treatment of locally advanced rectal cancer.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

Due to the assessment of computerized tomography with criteria from 1999, the role of radiotherapy in patients with diffuse large B-cell lymphoma with bulky or extranodal disease remains undefined.

The 5-year survival rate for patients with exon 20 insertion EFGR mutation is 8% in the frontline setting, worse than the survival rate of the 2 most common types of EGFR mutations in patients with advanced or metastatic non-small cell lung cancer.

Neither of the 2 current standards of care offers patients a cure.

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

Mounting concerns about availability of cancer drugs raise questions about the current supply

The phase 3 S1826 trial is the largest Hodgkin lymphoma study in NCTN history.

Chemotherapy may increase inflammatory biomarkers that can impact the diversity of the gut microbiome, leading to serious anthropomorphic changes among women treated for early-stage breast cancer.

A panel at the Advanced Topics for Oncology Pharmacy Professionals Summit discusses strategies to address patients’ fears and distrust of the medical and scientific community.

Effective implementation of the Inflation Reduction Act may allow legislators to shift their focus toward controversial pharmacy benefit manager practices, according to a panel discussion during the ATOPP Summit.

A cancer vaccine has shown efficacy in dogs, with implications for benefit in humans.

Zanubrutinib combined with obinutuzumab was previously granted both Fast Track and Orphan drug designations for patients with relapsed or refractory follicular lymphoma.

Despite a slew of barriers with patient management, pharmacists have the training and resources to advocate for better patient care and help patients with hematologic myeloproliferative neoplasms advocate for themselves.

Because of its prevalence in approximately 50% of breast cancers, the outcomes of HER2-low treatment have a significant impact on patient outcomes.

Updated phase 3 trial data provide practice-changing findings.